ClinicalTrials.gg
CompletedNCT06772207PRIME-AFUpdated Oct 29, 2026

Cardiac Rehabilitation Needs Among Individuals With Atrial Fibrillation

An observational study in Atrial Fibrillation (AF), sponsored by Esbjerg Hospital - University Hospital of Southern Denmark. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Esbjerg Hospital - University Hospital of Southern Denmark · Observational

How we know

Updated Oct 29, 2026Now CompletedStart date moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
30,882
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 176 studies in Atrial Fibrillation with a site in Denmark — 31 open to participants now, 48 under way, 3 of them phase 3. Atrial Fibrillation · Denmark.

Enrollment
3rd of 36
30,882 · median 391
Started
2025
with 6 others
Observational
36 of 176
5 open now
Registered
158th of 176
by date

Among the 176 studies in Atrial Fibrillation with a site in Denmark, this one is the 3rd largest by enrollment of the 36 observational ones that give a count, is one of 7 that started in 2025, is one of 36 observational ones, and was the 158th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

31 of the 176 studies in Atrial Fibrillation with a site in Denmark are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies in Atrial Fibrillation with a site in Denmark, or all of them as a file.
02

Study summary

The goal of this survey- and registry-based study is to learn about the cardiac rehabilitation needs of individuals with atrial fibrillation (AF). The main objectives of the study is to:

  1. describe needs for CR as part of secondary prevention among individuals with AF.
  2. assess eligibility and acceptance of referral to specific CR components based on individual patient-preferences, and their overlap with identified needs.
Read the detailed description

Atrial fibrillation (AF) is the most common cardiac arrhythmia in adults globally. It poses significant public health challenges and is associated with substantial morbidity and mortality. AF affects quality of life with an enlarged symptom burden. To improve life expectancy and quality of life, medical treatment along with risk factor management and cardiac rehabilitation is needed. In many countries, referral to cardiac rehabilitation remains low. Furthermore, no guidelines or evidence provides details on whom should be referred. Thus, we do not know how many individuals with AF presents with cardiac rehabilitation needs.

This study is a survey and registry-based study. Danish health registries are used to draw a population of individuals with incident AF in 2023-2024. Following the exclusion criteria, these will receive a survey covering the described outcomes which are used to investigate needs of rehabilitation. A statistical descriptive analysis will be performed to describe needs and patient-preferences for CR components.

03

Conditions studied

  • Atrial Fibrillation (AF)

Browse trials for

Keywords

  • Atrial Fibrillation
  • Cardiac rehabilitation
  • Needs
  • Secondary prevention
  • Primary care
  • Survey
  • Registry
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Registry-based. The study population is drawn from Danish Health Registries and receive an online questionnaire.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals with recidence in Denmark, 18 years of age or above, with a CPR number (personal identification number) registered with a diagnosis of incident AF in 2022 or 2023 (ICD-10: DI480*).

Exclusion criteria

Exclusion Criteria:

  • Death.
  • Name- and address protection.
  • Exemtion from using digital post.
  • Living in a nursing home.
  • A diagnosis of dementia.
  • Hospital admission or ambulant contacts due to mental illness within one year before diagnosis (except depression or anxiety).
  • Individuals receiving palliative care or treatment.
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
30,882 participants (actual)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • Respondents of electronic survey

    Population with incident AF in Denmark in 2023-2024

06

What researchers measure

Primary outcomes

  1. Atrial fibrillation related quality of life

    Atrial fibrillation related quality of life by ASTA HRQoL scale (The Arrhythmia-Specific questionnaire in Tachycardia and Arrhythmia). The ASTA HRQoL scale has 13 items and describes the arrhythmia's influence on daily life situation with a seven items physical subscale (items 1-5, 10 and 12) and a six items mental subscale (items 6-9, 11 and 13). We will be using both the total and subscale scores as recommended. The response alternatives from 0 to 3: "No (0), Yes, to a certain extent (1), Yes, quite a lot (2), Yes, a lot (3)". Scoring for the ASTA HRQoL total scale ranges from 0 (best possible HRQoL) to highest 39 (worst possible HRQoL). Higher scores reflect a worse effect on HRQoL due to the heart rhythm disturbance. ASTA's physical subscale ranges from 0 to 21 and the mental subscale ranges from 0 to18.

    Time frame: At enrollment

  2. Atrial fibrillation related symptom burden

    AF6 questionnaire. Patients chose a number on a Likert scale from 0 to 10, where 0 means no and 10 severe symptoms or difficulties. The scores of the six questions are added into a single global score. The recall period for the instrument is the most recent 7 days.

    Time frame: At enrollment

Secondary outcomes

  1. General well-being

    WHO5. The WHO-5 is a five-item scale measuring well-being and life satisfaction within the past 2 weeks and the scale is operationalized using a 0-100 score, with higher values indicating a higher level of well-being and life satisfaction. Scores below 50 indicate poor well-being.

    Time frame: At enrollment

  2. Anxiety

    ASS-2 has the purpose of screening for anxiety within the past 2 weeks. Higher score of ASS-2 indicates a higher symptom level of anxiety.

    Time frame: At enrollment

  3. Depression

    MDI-2 has the purpose of screening for depression within the past 2 weeks. Higher score indicates a higher symptom level of depression.

    Time frame: At enrollment

  4. Medicine adherence

    MARS-5 (Medication Adherence Report Scale). Items scored as 5 = never to 1 = always, i.e. high scores = high adherence. Scores are added together to form a scale score (range = 5 to 25). An adjusted mean score is calculated by dividing the scale mean by the number of items in the scale (range 1-5).

    Time frame: At enrollment

  5. Risk factor status

    Obesity, physical inactivity, smoking and alcohol habits

    Time frame: At enrollment

  6. Comorbidity

    Hypertension, diabetes, sleep apnoea, other cardiac diseases

    Time frame: At enrollment

Other outcomes

  1. General health status

    EQ-5D-5L. Responses are coded as single-digit numbers expressing the severity level selected in each dimension. For instance, 'slight problems' (e.g. 'I have slight problems in walking about') is always coded as '2'. The digits for the five dimensions can be combined in a 5-digit code that describes the respondent's health state; for instance, 21111 means slight problems in the mobility dimension and no problems in any of the other dimensions. The EQ VAS records the respondent's overall current health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' (100) and 'The worst health you can imagine' (0). The EQ VAS provides a quantitative measure of the patient's perception of their overall health.

    Time frame: At enrollment

  2. Demographic data

    Age, gender, civil status, living situation, region of Denmark, educational level, occupational status, ethnicity, socio-economic classification and family disposable income.

    Time frame: At enrollment

  3. Outcomes important for the overall assessment of cardiac rehabilitation needs

    Questions regarding family relations, health literacy (HLS-EU-Q12), management of heart disease, previous provided information of cardiac rehabilitation and motivation for these interventions forwardly.

    Time frame: At enrollment

07

Study locations

1 site
  • Esbjerg Hospital - University Hospital of Southern Denmark
    Esbjerg, Denmark
08

References and documents

Publications

  • Elnegaard CM, Borregaard B, Risom SS, Tveskov C, Bech M, von Bornemann Hjelmborg J, Eilso J, Hedegaard AM, Stege Bojer A, Darkner S, Albertsen AE, Joensen AM, Brandes A, Zwisler AD. Cardiac rehabilitation in atrial fibrillation: a protocol for a Danish survey and registry-based study (PRIME-AF). BMJ Open. 2025 Dec 24;15(12):e107042. doi: 10.1136/bmjopen-2025-107042. PubMed 41448694 ↗

Individual participant data

Plan to share: No — Unless follow-up studies using the same study population is planned later on, data (IPD) will not be shared.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jun 2025 to primary completion in Dec 2025, 6 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Jul 2025 → Dec 2025 and completion Jul 2025 → Dec 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2025
First posted
Jan 13, 2025
StartActual
Jun 10, 2025
Primary completionActual
Dec 31, 2025was Jul 2025
CompletionActual
Dec 31, 2025was Jul 2025
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Completed
changed Oct 29, 2026
Sites
1 site added, 1 site removed
Show site
  • Esbjerg Hospital - University Hospital of Southern Denmark · Esbjerg, Denmark
Show 1 removed
  • Odense University Hospital · Odense, Denmark
Oct 29, 2026
Start date
Jun 11, 2025→Jun 10, 2025
Oct 29, 2026
Primary completion
Jul 14, 2025→Dec 31, 2025 (actual)
Oct 29, 2026
Study completion
Jul 14, 2025→Dec 31, 2025 (actual)
Oct 29, 2026
Enrollment
30000 (estimated)→30882 (actual)
Oct 29, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41448694 ↗
Oct 29, 2026
Sponsor
Odense University Hospital→Esbjerg Hospital - University Hospital of Southern Denmark
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Enrolling by invitation→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41448694 ↗
    1 site added, 1 site removed
    Show site
    • Esbjerg Hospital - University Hospital of Southern Denmark · Esbjerg, Denmark
    Show 1 removed
    • Odense University Hospital · Odense, Denmark
    Start date Jun 11, 2025→Jun 10, 2025
    Primary completion Jul 14, 2025→Dec 31, 2025 (now actual)
    Study completion Jul 14, 2025→Dec 31, 2025 (now actual)
    Enrollment 30000 (estimated)→30882 (actual)
    Sponsor Odense University Hospital→Esbjerg Hospital - University Hospital of Southern Denmark
    + 4 other changes: identifiers, verification date, oversight details and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06772207
Lead sponsor
Esbjerg Hospital - University Hospital of Southern Denmark
Responsible party
Axel Brandes (Clinical professor, Esbjerg Hospital - University Hospital of Southern Denmark) — Principal investigator
First posted
Jan 13, 2025
Start date
Jun 10, 2025
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025
Last update
Oct 29, 2026

Study contacts

Axel Brandes, Professor, cardiologist
study chair · Department of Cardiology, Esbjerg and Grindsted Hospital - University Hospital of Southern Denmark, Esbjerg, Denmark.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion